Dr. Reddy's: Expects Strong Performance In Q3 And Q4 After Fixing Semaglutide Problems.

 30 Jul 2026 09:20 AM

Dr. Reddy's: Expects Strong Performance In Q3 And Q4 After Fixing Semaglutide Problems.

DR Reddy's: Receives Approval From Thai FDA For Nuzolvance (Zolifloxacin)

 27 Jul 2026 02:40 PM

DR Reddy's: Receives Approval From Thai FDA For Nuzolvance (Zolifloxacin)

Dr Reddy's Laboratories: Guidance - Management maintains its guidance for EBITDA margin to be in the neighborhood of 20% for the next quarter, even without semaglutide, and expects higher margins with semaglutide resumption in November.- Comcall Update

 23 Jul 2026 09:06 AM

Dr Reddy's Laboratories: Guidance - Management maintains its guidance for EBITDA margin to be in the neighborhood of 20% for the next quarter, even without semaglutide, and expects higher margins with semaglutide resumption in November.- Comcall Update

Dr Reddy's Laboratories: Guidance - The company plans to resume semaglutide commercial supplies by November, aiming to provide 6 million to 7 million pens between November and March, with high confidence in demand and partner relationships.- Comcall Update

 23 Jul 2026 09:06 AM

Dr Reddy's Laboratories: Guidance - The company plans to resume semaglutide commercial supplies by November, aiming to provide 6 million to 7 million pens between November and March, with high confidence in demand and partner relationships.- Comcall Update

Dr Reddy's Laboratories: Guidance - R&D spend is guided to be in the range of 7% to 8% of revenues, with most investment directed towards products post-2034.- Comcall Update

 23 Jul 2026 09:06 AM

Dr Reddy's Laboratories: Guidance - R&D spend is guided to be in the range of 7% to 8% of revenues, with most investment directed towards products post-2034.- Comcall Update

Dr Reddy's Laboratories: Guidance - The effective tax rate (ETR) is expected to be between 24% to 25% on a normalized basis for the full year.- Comcall Update

 23 Jul 2026 09:07 AM

Dr Reddy's Laboratories: Guidance - The effective tax rate (ETR) is expected to be between 24% to 25% on a normalized basis for the full year.- Comcall Update

Dr Reddy's Laboratories: Guidance - CapEx cash outflow for the current year is projected to be around INR1,800 crore, down from the previous INR2,500-INR2,700 crore range, and is expected to stay at that level next year due to continuous investments in biosimilars and peptides.- Comcall Update

 23 Jul 2026 09:07 AM

Dr Reddy's Laboratories: Guidance - CapEx cash outflow for the current year is projected to be around INR1,800 crore, down from the previous INR2,500-INR2,700 crore range, and is expected to stay at that level next year due to continuous investments in biosimilars and peptides.- Comcall Update

Dr Reddy's Laboratories: Guidance - The biologics business is expected to become profitable upon the launch of abatacept, with the goal date for US approval in mid-December 2026.- Comcall Update

 23 Jul 2026 09:07 AM

Dr Reddy's Laboratories: Guidance - The biologics business is expected to become profitable upon the launch of abatacept, with the goal date for US approval in mid-December 2026.- Comcall Update

Dr Reddy's Laboratories: Guidance - The company is targeting 27 new product launches in the US for the rest of the year, with a specific launch in the next couple of weeks expected to generate tens of millions of dollars.- Comcall Update

 23 Jul 2026 09:07 AM

Dr Reddy's Laboratories: Guidance - The company is targeting 27 new product launches in the US for the rest of the year, with a specific launch in the next couple of weeks expected to generate tens of millions of dollars.- Comcall Update

Dr. Reddy's: Citi on Dr. Reddy's Maintains Sell with Target Price ₹1,040 as margins fell to multi-year lows, weak US business and rising costs hurt profitability despite expected semaglutide supply recovery in 2HFY27.

 23 Jul 2026 08:50 AM

Dr. Reddy's: Citi on Dr. Reddy's Maintains Sell with Target Price ₹1,040 as margins fell to multi-year lows, weak US business and rising costs hurt profitability despite expected semaglutide supply recovery in 2HFY27.

Dr. Reddy's: CLSA on Dr. Reddy's Maintains Hold with Target Price ₹1,240 as gSemaglutide issues and higher freight costs hurt margins, though management expects US growth and margin recovery after November 2026.

 23 Jul 2026 08:50 AM

Dr. Reddy's: CLSA on Dr. Reddy's Maintains Hold with Target Price ₹1,240 as gSemaglutide issues and higher freight costs hurt margins, though management expects US growth and margin recovery after November 2026.

Dr. Reddy's: JPMorgan on Dr. Reddy's Maintains Underweight with Target Price ₹1,100 as weak core profitability, higher SG&A and freight costs outweigh recovery hopes from semaglutide and Abatacept launches.

 23 Jul 2026 08:50 AM

Dr. Reddy's: JPMorgan on Dr. Reddy's Maintains Underweight with Target Price ₹1,100 as weak core profitability, higher SG&A and freight costs outweigh recovery hopes from semaglutide and Abatacept launches.

Dr. Reddy's: Jefferies on Dr. Reddy's Maintains Underperform with Target Price ₹1,040 as Q1 margins missed sharply on weak US business, higher input costs and semaglutide delays, prompting FY27-29 earnings cuts.

 23 Jul 2026 08:50 AM

Dr. Reddy's: Jefferies on Dr. Reddy's Maintains Underperform with Target Price ₹1,040 as Q1 margins missed sharply on weak US business, higher input costs and semaglutide delays, prompting FY27-29 earnings cuts.

Dr Reddy's: Co Executive Reports Higher Freight Costs From Middle East Issues And Increased Solvent Prices Affect EBITDA This Quarter.

 22 Jul 2026 05:41 PM

Dr Reddy's: Co Executive Reports Higher Freight Costs From Middle East Issues And Increased Solvent Prices Affect EBITDA This Quarter.

Dr Reddy's: Launches Generic Semaglutide Tablets In India

 22 Jul 2026 05:42 PM

Dr Reddy's: Launches Generic Semaglutide Tablets In India

Dr Reddy's: Reports 2.40 Billion Rupee Impact From Semaglutide API In Q1 FY27

 22 Jul 2026 04:59 PM

Dr Reddy's: Reports 2.40 Billion Rupee Impact From Semaglutide API In Q1 FY27

Dr. Reddy's: Co. Delays Semaglutide Supply After Some Batches Don't Meet Quality Standards; No Timeline Given For When Supply Will Resume. - Newspaper

 10 Jul 2026 09:03 AM

Dr. Reddy's: Co. Delays Semaglutide Supply After Some Batches Don't Meet Quality Standards; No Timeline Given For When Supply Will Resume. - Newspaper

Dr Reddy's Laboratories: Reports Issues With Semaglutide Batches Due To API Problems; Investigating And Delaying Supplies; No Safety Or Regulatory Concerns.

 09 Jul 2026 09:19 AM

Dr Reddy's Laboratories: Reports Issues With Semaglutide Batches Due To API Problems; Investigating And Delaying Supplies; No Safety Or Regulatory Concerns.

Dr. Reddy’s: Jefferies on Dr. Reddy’s Maintains Underperform with Target Price of ₹1,040 as it sees only ~14% upside even in a blue-sky scenario, remains bearish versus its bullish stance on Mankind, and believes Dr. Reddy’s upside is limited while Cipla’s bull case depends on unlikely timely US drug approvals.

 09 Jul 2026 08:58 AM

Dr. Reddy’s: Jefferies on Dr. Reddy’s Maintains Underperform with Target Price of ₹1,040 as it sees only ~14% upside even in a blue-sky scenario, remains bearish versus its bullish stance on Mankind, and believes Dr. Reddy’s upside is limited while Cipla’s bull case depends on unlikely timely US drug approvals.

Dr Reddy's: Faces Challenges As Apotex Gets Approval For Generic Wegovy, Risking GLP-1 Market Potential; Citi Signals Downside, Keeps 'Sell' Rating With ₹1,070 Target.

 01 Jul 2026 12:04 PM

Dr Reddy's: Faces Challenges As Apotex Gets Approval For Generic Wegovy, Risking GLP-1 Market Potential; Citi Signals Downside, Keeps 'Sell' Rating With ₹1,070 Target.